HC Wainwright & Co. Reiterates Buy Rating on Avidity Biosciences, Inc. (RNA)

Market Context

Avidity Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $12.84 with a market capitalization of $9.4B. The stock has declined 72.4% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Avidity Biosciences, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Avidity Biosciences, Inc.

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 14, 2026	HC Wainwright & Co.	Buy	N/A
Aug 06, 2026	HC Wainwright & Co.	Buy	N/A
Jun 18, 2026	Cantor Fitzgerald	Overweight	N/A
May 15, 2026	Leerink Partners	Outperform	N/A
Mar 11, 2026	Wells Fargo	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View RNA Stock Page